BrainStorm announced that the FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn in amyotrophic lateral sclerosis – ALS -. The meeting is scheduled to take place on December 6. Brainstorm will discuss plans for a Special Protocol Assessment with the FDA to agree on the overall protocol design for a confirmatory Phase 3 trial in ALS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCLI:
- Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Meet with FDA for New Treatment Plans
- BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
- BCLI Earnings this Week: How Will it Perform?
- Largest borrow rate increases among liquid names
- BrainStorm launches strategic realignment prioritizing NurOwn in ALS
